▲ +239.29% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Tiziana Life Sciences in the last 3 months. The average price target is $9.50, with a high forecast of $11.00 and a low forecast of $8.00. The average price target represents a 239.29% upside from the last price of $2.80.
The current consensus among 2 contributing investment analysts is to buy stock in Tiziana Life Sciences. This Buy consensus rating has held steady for over two years.
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.